Northern Trust Corp Has $9.32 Million Stock Holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Northern Trust Corp grew its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 12.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,014,743 shares of the medical technology company’s stock after purchasing an additional 108,959 shares during the quarter. Northern Trust Corp owned about 0.72% of Alphatec worth $9,315,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. lifted its position in shares of Alphatec by 36.5% in the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company’s stock valued at $45,800,000 after buying an additional 1,334,780 shares during the last quarter. Marshall Wace LLP raised its stake in Alphatec by 139.2% in the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company’s stock valued at $16,278,000 after acquiring an additional 1,032,070 shares during the period. Emerald Advisers LLC lifted its holdings in Alphatec by 112.4% during the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company’s stock valued at $13,366,000 after purchasing an additional 770,586 shares during the last quarter. Tudor Investment Corp ET AL boosted its position in Alphatec by 295.4% during the fourth quarter. Tudor Investment Corp ET AL now owns 585,865 shares of the medical technology company’s stock worth $5,378,000 after purchasing an additional 437,690 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Alphatec by 119.3% in the fourth quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company’s stock valued at $6,079,000 after purchasing an additional 360,258 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ATEC shares. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Piper Sandler reiterated an “overweight” rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Barclays lifted their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and an average target price of $17.89.

Insider Activity at Alphatec

In other news, CEO Patrick Miles sold 32,393 shares of Alphatec stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $10.89, for a total transaction of $352,759.77. Following the sale, the chief executive officer now directly owns 5,940,391 shares of the company’s stock, valued at approximately $64,690,857.99. This trade represents a 0.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Sponsel sold 12,946 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $10.73, for a total value of $138,910.58. Following the sale, the executive vice president now owns 722,128 shares in the company, valued at approximately $7,748,433.44. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,945 shares of company stock valued at $1,416,352. 20.90% of the stock is owned by insiders.

Alphatec Price Performance

Alphatec stock opened at $12.96 on Friday. The stock’s fifty day moving average price is $10.73 and its two-hundred day moving average price is $10.39. The firm has a market cap of $1.89 billion, a PE ratio of -10.13 and a beta of 1.06. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $13.03.

Alphatec (NASDAQ:ATEC) last released its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the previous year, the company earned ($0.34) earnings per share. The firm’s revenue for the quarter was up 22.2% on a year-over-year basis. As a group, research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.